C4 Therapeutics (CCCC) Change in Acquisitions & Divestments (2019 - 2026)

C4 Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $57.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 4.13% year-over-year to $57.0 million; the TTM figure through Mar 2026 stood at $221.3 million (down 5.26% YoY), while the FY2025 annual figure was $219.1 million, down 6.07% from the prior year.
• Change in Acquisitions & Divestments was $57.0 million for Q1 2026 at C4 Therapeutics, up from $52.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $90.3 million in Q3 2023 to a low of $51.2 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $63.7 million across 5 years, with a median of $64.2 million in 2023.
• Biggest YoY gain for Change in Acquisitions & Divestments was 44.85% in 2022; the steepest drop was 37.05% in 2022.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $67.1 million in 2022, then climbed by 4.35% to $70.0 million in 2023, then retreated by 22.19% to $54.4 million in 2024, then dropped by 3.86% to $52.3 million in 2025, then increased by 8.94% to $57.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $57.0 million (Q1 2026), $52.3 million (Q4 2025), and $51.2 million (Q3 2025), per Business Quant data.